Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020 - Flegar, L; Thoduka, SG; Librizzi, D (Eur J Nucl Med Mol Imaging, 2023)
et al.